The health burden of non-communicable neurological disorders in the USA between 1990 and 2017

Shahrzad Bazargan-Hejazi,1 Kaveh Dehghan,2 Cristina Edwards,3 Najmeh Mohammadi,4 Setareh Attar,2 Mohammad Ali Sahraian5 and Sharareh Eskandarieh5

In this observational study, using the Global Burden of Disease and Risk Factors Study, we aimed to (i) report the magnitude of health loss due to non-communicable neurological disorders in the USA in 2017 by sex, age, years and States and (ii) to identify non-communicable neurological disorders attributable environmental, metabolic and behavioural risk factors. We provide estimates of the burden of non-communicable neurological disorders by reporting disability-adjusted life-years and their trends from 1990 to 2017 by age and sex in the USA. The non-communicable neurological disorders include migraines, tension-type headaches, multiple sclerosis, Alzheimer’s disease and other dementias, Parkinson’s disease, epilepsy, motor neuron diseases and other neurological disorders. In 2017, the global burdens of non-communicable neurological disorders were 1444.41 per 100 000, compared to the USA burden of 1574.0. Migraine was the leading age-standardized disability-adjusted life-years 704.7 per 100 000, with Alzheimer’s disease and other dementias (418.7), and epilepsy (123.8) taking the second and third places, respectively. Between 1990 and 2017, the age-standardized disability-adjusted life-years rates for aggregate non-communicable neurological disorders relative to all cause increased by 3.42%. More specifically, this value for motor neuron diseases, Parkinson’s disease and multiple sclerosis increase by 20.9%, 4.0%, 2.47%, 3.0% and 1.65%, respectively. In 2017, the age-standardized disability-adjusted life-years rates for the aggregate non-communicable neurological disorders was significantly higher in females than the males (1843.5 versus 1297.3 per 100 000), respectively. The age-standardized disability-adjusted life-years rates for migraine were the largest in both females (968.8) and males were (432.5) compared to other individual non-communicable neurological disorders. In the same year, the leading non-communicable neurological disorders age-standardized disability-adjusted life-years rates among children <9 was epilepsy (216.4 per 100 000). Among the adults aged 35–60 years, it was migraine (5792.0 per 100 000), and among the aged 65 and above was Alzheimer’s disease and other dementias (78 800.1 per 100 000). High body mass index, smoking, high fasting plasma glucose and alcohol use were the attributable age-standardized disability-adjusted life-years risks for aggregate and individual non-communicable neurological disorders. Despite efforts to decrease the burden of non-communicable neurological disorders in the USA, they continue to burden the health of the population. Children are most vulnerable to epilepsy-related health burden, adolescents and young adults to migraine, and elderly to Alzheimer’s disease and other dementias and epilepsy. In all, the most vulnerable populations to non-communicable neurological disorders are females, young adults and the elderly.
Introduction

Neurological disorders (NDs) are heterogeneous diseases that affect the body’s autonomic, peripheral and central nervous system. There are over 600 NDs affecting a range of neonatal to elderly and may be categorized by the system they affect (Janca et al., 2006). These NDs may be classified as communicable (able to be transmitted to one sufferer to another) or non-communicable (not directly transmissible) (Bruzon et al., 2009). Non-communicable neurological disorders (NCNDs), including among others Alzheimer’s disease and other dementia (ADOD), Parkinson’s disease, epilepsy, as well as migraines and tension headaches, are prevalent in high-income countries (GBD 2015 Neurological Disorders Collaborator Group, 2017). In the USA, NCNDs affect 14% of the American population and are expected to ‘triple by 2050’ (Saadi et al., 2017). It is estimated that
the economic burden of NCNDs in the USA is $800 billion annually (Gooch et al., 2017).

As indicated by previous studies, susceptibility to certain NCNDs varies by age and sex (Amatniek et al., 2010; Vina and Ana, 2010; Peterlin et al., 2011). For example, migraines are more prevalent in females than in males (Peterlin et al., 2011). Multiple sclerosis showed early onset in women than men, and peak at the age of 30 (Harbo et al., 2014). Alzheimer’s disease and other dementia have early onset as early as 30–65 years of age and more prevalent in women than men (Vina and Ana, 2010). Research in Parkinson’s disease shows male–female differences in the age and presentation of Parkinson’s disease, where women diagnosed with this condition are on average 2.1 years older than men (53.4 versus 51.3), and are more likely to experience tremor as the initial symptom than rigidity (Haaxma, et al., 2007; Miller and Cronin-Golomb, 2010).

In addition to sex and age, environmental, metabolic and behavioural risk factors may also increase susceptibility to NCNDs (Ahmed et al., 2016). The environmental risk factors that pose a threat are inorganic and organic hazards, exposure to toxic metals (aluminium, copper), pesticides (organo-chlorine and organophosphate insecticides), industrial chemicals (flame retardants) and air pollutants (particulate matter). The long-term exposure to these environmental risk factors has revealed alterations in the pathways associated with ADOD and may account for 30% of ADOD risk factors (Yegambaram et al., 2015). High body mass index (BMI) and high fasting plasma glucose (FPG) are both metabolic risk factors found in ADOD. A 3.10-fold increase of ADOD is shown when comparing individuals with normal BMI (18.5–24.9) to obese individuals (BMI > 30) (Whitmer et al., 2007). This increase is related to the accumulation of β-amyloid protein in ADOD (Barron et al., 2013). Drugs are behavioural risk factors that alter neuronal function, their transmitters and eventually neuronal circuits (Neiman et al., 2000). Alcohol is known to trigger seizures and induce epilepsy; however, the mechanism by which alcohol prompts seizures is unknown (Gordon and Devinsky, 2001). Smoking also serves as an additional behavioural risk factor for multiple sclerosis. Those who smoke have 1.5 higher chances of developing multiple sclerosis (Belbasis et al., 2015).

In the current study, we aimed: (i) to describe the trend of NCNDs related health burden in the USA from 1990 to 2017, (ii) to report the magnitude of health loss due to NCNDs in the USA in 2017 by sex and age and (iii) to identify NCNDs risk factors in the USA. The results of this study will inform interventions to target segments of the population that are most impacted by the burden of NCNDs. Funding agencies and policymakers can also benefit from the findings of this study in allocating appropriate funds and developing a policy plan to reduce the physical, mental, social and economic burden of NCNDs in the US population.

Materials and methods

Study dataset and data source

The source of data for the current study is the Global Burden of Disease Study (GBD). GBD’s study goal is to comprehensively and globally quantify and estimate premature deaths, deaths, disability and burden of disease due to disease, injuries and risk factors on annual bases. These population estimates span the period between 1990 and 2017 (Institute for Health Metrics and Evaluation, IHME https://vizhub.healthdata.org/gbd-compare/). GBD produces estimates by collecting evidence from various fatal and non-fatal data sources. The fatal data, which are used to estimate years of life lost, include vital registrations, verbal autopsies, surveillance data, hospital records, census/surveys and population-based cancer registries (GBD Neurological Disorders Collaborator Group, 2017, 2019). The fatal data are analysed with the Cause of Death Ensemble Model (CODEm) tool (Feigin et al., 2019). The non-fatal data are used to calculate years of life lived with disability and are collected by reviewing scientific literature, population surveys, hospital outpatient data, surveillance data, disease registries and others (GBD Neurological Disorders Collaborator Group, 2017).

The causes of disease or injury in the GBD Study are classified into four levels. The first level includes three main groups; communicable, maternal, and neonatal conditions and nutritional deficiencies all in one group, non-communicable disease in the second group, and injuries in the third group. With the advance of levels from 1 to 4, the number of diseases and injuries (i.e. sub-causes) in each main group increases. Level 4 has the most detailed number of sub-causes (Lopez et al., 2006). NCNDs belong to the second group (i.e. non-communicable disease), and at Level 4, it contains nine sub-causes, including migraines, tension-type headaches, multiple sclerosis, ADOD, Parkinson’s, epilepsy, motor neuron, and other NDs. We used these sub-causes for the current study. Additionally, GBD Study uses 23 age categories that range from 0–6 days to 95+ and 84 risk factors, all listed under three general areas of environmental/occupational, behavioural and metabolic risk factors (Salomon et al., 2015; Institute for Health Metrics and Evaluation, IHME, 2017). For a risk to be included in this list, there should be sufficient empirical evidence for a causal relationship between the risk and the disease outcome (Institute for Health Metrics and Evaluation, IHME http://www.healthdata.org/gbd/about).

Statistical analysis

GBD study uses DisMod-MR 2.1, a Bayesian meta-regression tool, to analyse non-fatal data (Feigin et al., 2019). For the current study, we provide estimates of the burden of NCNDs as measured by disability-adjusted
life-years (DALYs) and their trends from 1990 to 2017 by age and sex in the USA. The term DALYs refers to the sum of years lost due to premature death and years lived with disability (GBD Collaborator et al., 2016). For all estimates, GBD reports the 95% uncertainty intervals (UIs), which are calculated by the IHME staff. The lower and upper bounds of the UI are determined based on the 25th and 975th values of the ordered 1000th values. Significance of differences is established if 975 or more of the ordered 1000 values of difference were on either side of zero (GBD Neurological Disorders Collaborator Group, 2017).

**Data availability**

Data available using the following URL: https://vizhub.healthdata.org/gbd-compare/ and http://ghdx.healthdata.org/gbd-results-tool.

**Results**

**NCNDs in the USA**

In 2017, NCNDs ranked 6th among the top 10 leading non-communicable causes of DALYs in the USA (Supplementary Fig. 1), similar to the global estimate (Supplementary Fig. 2). A ranking that did not shift from 1990, and contributed to 6.7 million (UI 8.1–5.6 million) DALYs, up from 4.9 million in 1990 (Table 1).

In 1990, migraine was the largest contributor to DALYs (1.86 million). However, ADOD was the largest contributor to total DALYs (2.40 million) in 2017. Between 1990 and 2017, the aggregate NCNDs age-standardized DALY rates increased by 3.42%, and of separate NCNDs, epilepsy had the largest increase in DALY rates (5.46%). Migraine ranked 1st both in 1990 and 2017, accounting for 694.1 (UI 443.6–1008.1) and 704.78 (UI 445.99–1020.5) age-standardized DALY rates, respectively. This followed by ADOD, epilepsy and tension headache (Table 1).

As illustrated in Table 2, in 2017, aggregate NCNDs contributed to 6.74% of total DALYs up from 5.68% in 1990. ADOD was the largest contributor accounting for 2.54% of total DALYs. In 1990, migraines accounted for the largest proportion (2.35%) of DALYs relative to total DALYs. Between 1990 and 2017, the proportion of DALYs due to the aggregate NCNDs relative to DALYs from all other causes increased by 18.5%. The largest increase in the proportions was evident in Parkinson’s disease (58.5%), followed by motor neuron disease (55.3%), multiple sclerosis and ADOD.

**NCNDs related DALYs by sex**

In 2017, 2.6 million males (UI 2.19–3.10 million) and 4.17 million females (3.40–5.02 million) were estimated to have NCNDs. Across the aggregate of eight NCNDs, the age-standardized DALY rates were higher for females [1843.4 (UI 1410.3–2330.8)] than males [1297.3; (UI: 1064.9–1581.5)]. When examined separately, migraine and ADOD were the leading NDs for females, responsible for 1.66 million (1.07–2.37 million), and 1.60 million (1.52–1.69 million) DALYs, respectively. For males, the leading NCNDs were ADOD followed by migraine accounting for 9.43 million (8.93
million–9.92 million) and 7.38 million (4.62–1.10 million) DALYs, respectively. In both 1990 and 2017, there was a higher age-standardized DALY rates in females than males for ADOD, migraine, multiple sclerosis and tension headache (Table 3). Whereas the burden of Parkinson’s disease, epilepsy, motor neuron diseases and other NDs (i.e. NDs that are not explicitly estimated) was higher in males (Table 3).

The age-standardized rate of DALYs for aggregate NCNDs increased by 4.05% and 3.57% in males and females, respectively, from 1990 to 2017 (Table 3). During this time, the percent change in DALY numbers and age-standardized rates for females increased across separate NCNDs. For males, except for other NDs that decreased by 4.79%, the DALY numbers and age-standardized rates of separate NCNDs increased. The highest

| NCNDs                  | 1990 Rank | 1990 DALYs in million | 1990 DALY per 100 000 | 2017 Rank | 2017 DALYs in millions | 2017 DALY per 100 000 | 1990–2017 Rate % change |
|------------------------|-----------|-----------------------|----------------------|-----------|------------------------|----------------------|------------------------|
| Aggregate NCNDs        | 5         | 4.49                  | 1521.9               | 6         | 6.77                   | 1574.0               | 3.42                   |
|                        |           | (3.61–5.50)           | (1.00–2.69)          |           | (5.64–8.13)            | (1.00–2.69)          |                        |
| Migraine               | 1         | 1.86                  | 694.1                | 1         | 2.40                   | 704.7                | 1.53                   |
|                        |           | (1.19–2.69)           | (0.65–0.84)          |           | (1.53–3.44)            | (0.65–0.84)          |                        |
| ADOD*                  | 2         | 1.47                  | 413.6                | 2         | 2.55                   | 418.7                | 1.24                   |
|                        |           | (1.39–1.57)           | (1.04–1.67)          |           | (2.42–2.67)            | (1.04–1.67)          |                        |
| Epilepsy               | 3         | 0.30                  | 117.4                | 3         | 0.41                   | 123.8                | 5.46                   |
|                        |           | (0.20–0.44)           | (0.10–0.23)          |           | (0.25–0.62)            | (0.10–0.23)          |                        |
| Tension-type headache  | 4         | 0.26                  | 76.9–172.6           | 4         | 0.34                   | 75.1–187.4           | 0.00                   |
|                        |           | (0.14–0.41)           | (0.09–0.18)          |           | (0.19–0.55)            | (0.09–0.18)          |                        |
| Parkinson's disease    | 6         | 0.20                  | 54.4–154.3           | 5         | 0.41                   | 96.5                 | 0.00                   |
|                        |           | (0.18–0.23)           | (0.15–0.18)          |           | (0.34–0.44)            | (0.15–0.18)          |                        |
| Other NDs              | 5         | 0.16                  | 53.4–67.8            | 6         | 0.24                   | 67.4                 | 1.83                   |
|                        |           | (0.15–0.18)           | (0.15–0.18)          |           | (0.20–0.28)            | (0.15–0.18)          |                        |
| Multiple sclerosis     | 7         | 0.11                  | 37.4–47.6            | 8         | 0.19                   | 42.9                 | 20.9                   |
|                        |           | (0.09–0.13)           | (0.09–0.13)          |           | (0.16–0.23)            | (0.09–0.13)          |                        |

* Alzheimer’s disease and other dementias.
percent change increase for females was in multiple sclerosis (19.9%), motor neuron disease (16.3%) and other NDs (11.2%), respectively. For males, they were in Parkinson’s disease (29.3%), motor neuron diseases (23.0%) and multiple sclerosis (11.1%). Altogether, females were more impacted by the burden of the NCNDs as an aggregate or when examined separately.

NCNDs related DALYs by age
In 2017, children between the ages of 5 and 9 years experienced the largest age-standardized DALY rates due to epilepsy [118.3 (UI 63.29–194.50)], raising 14% from 103.6 (UI 57.1–171.0) in 1990, burdening 24 136.4 (UI 12 911.0–3968.4) children in this age category. In the same year, age-standardized DALY rates due to migraines were highest in people aged 35 years to 39 years [1274.2 (UI 825.6–1833.1)] followed by people aged 40–44 years [1261.9 (UI 828.5–1784.7)] causing 461 930.5 (UI 374 012.1–671 380.5) number of DALYs. ADOD age-standardized DALYs rates rapidly increased after age 65 years and became the dominant NCND burden for individuals between the ages of 65 and 95 years, accounting for 74 787.64 (UI 70 407.78–79 585.73) DALY rates

Table 2 Percent of total DALYs and rank of all age DALYs due to NCNDs for both sexes, in the USA, 1990 and 2017

| NCNDs          | 1990 DALYs proportion relative to DALYs from all causes | 1990 % Rank | 1990 DALYs proportion relative to DALYs from all causes | 1990 % Rank | 1990–2017 Proportion % change |
|----------------|----------------------------------------------------------|------------|----------------------------------------------------------|------------|-------------------------------|
| Aggregate NCNDs| 5.68% (4.93–6.55%)                                       | 5          | 6.74% (5.98–7.6%)                                       | 5          | 18.5                          |
| ADODa          | 1.88% (1.74–2.02%)                                       | 2          | 2.54% (2.33–2.76%)                                      | 1          | 35.5                          |
| Migraine       | 2.35% (1.61–3.20%)                                       | 1          | 2.38% (1.65–3.23%)                                      | 2          | 1.4                           |
| Epilepsy       | 0.38% (0.26–0.55%)                                       | 3          | 0.41% (0.26–0.61%)                                      | 3          | 7.3                           |
| Parkinson’s disease | 0.26% (0.23–0.31%)                                     | 5          | 0.41% (0.34–0.45%)                                      | 4          | 58.5                          |
| Tension-type headache | 0.33% (0.20–0.50%)                                  | 4          | 0.35% (0.21–0.52%)                                      | 5          | 4.9                           |
| Other NDs      | 0.21% (0.19–0.24%)                                       | 6          | 0.24% (0.20–0.28%)                                      | 6          | 12.8                          |
| Multiple sclerosis | 0.15% (0.13–0.17%)                                   | 7          | 0.20% (0.17–0.22%)                                      | 7          | 38.6                          |
| Motor neuron disease | 0.13% (0.11–0.14%)                                  | 8          | 0.20% (0.17–0.22%)                                      | 8          | 56.3                          |

*Alzheimer’s disease and other dementias.

Table 3 NCNDs related DALY counts, age-standardized rates and percent change for male and female in the USA, 1990, 2017

|          | 1990  | 1990          | 1990          | 2017  | 2017          | 2017          | 1990–2017|
|----------|-------|--------------|--------------|-------|--------------|--------------|----------|
|          | Number| Rate 100 000 | Percent change | Number| Rate 100 000 | Percent change | Number  |
| Global   | 28 695.611.1 | 131.2 | 12 000 | 61.0 | 3.00 | 24 888.11 | 1670.9 | 64 907 538.6 | 1606.9 | 61.00 | 4.00 |
| NCNDs    | 1 612 027.4 | 1246.8 | 61.3 | 4.05 | 2 878 102.3 | 1780.0 | 4 177 905.2 | 1843.4 | 45.16 | 3.57 |
| Motor neuron disease | 54 672.1 | 41.8 | 1 101 385.2 | 51.4 | 107.1 | 23.02 | 45 231.0 | 30.1 | 85 782.8 | 35.0 | 89.65 | 16.60 |
| ADODa    | 482 495.8 | 377.9 | 943 268.4 | 385.3 | 95.5 | 1.95 | 994 851.4 | 429.7 | 1 609 481.9 | 439.0 | 61.78 | 2.18 |
| Parkinson’s disease | 108 734.4 | 80.4 | 255 446.8 | 104.1 | 134.9 | 29.39 | 95 185.0 | 44.0 | 156374.3 | 48.3 | 64.28 | 9.80 |
| Epilepsy  | 151 278.8 | 121.0 | 203 769.0 | 124.6 | 34.7 | 2.92 | 152 690.0 | 114.0 | 212 174.6 | 123.1 | 38.96 | 7.94 |
| Multiple sclerosis | 38 104.6 | 28.1 | 66 147.5 | 31.2 | 73.5 | 11.13 | 77 387.9 | 52.0 | 137 862.6 | 62.4 | 78.14 | 19.90 |
| Migraine  | 567 995.1 | 432.5 | 738 062.6 | 439.3 | 29.9 | 1.57 | 1 292 043.9 | 949.8 | 1 666 257.9 | 968.8 | 28.96 | 2.00 |
| Tension-type headache | 111 537.5 | 85.1 | 150 348.8 | 85.2 | 34.8 | 0.18 | 149 834.1 | 107.2 | 199 302.3 | 107.5 | 33.02 | 0.33 |
| Other NDs | 97 208.9 | 79.7 | 131 108.1 | 75.9 | 34.8 | 4.79 | 70 876.9 | 53.0 | 110 668.4 | 59.0 | 56.14 | 11.2 |

*Alzheimer’s disease and other dementias.
Supplementary Table 1) and 2.4 million (UI 1.73–1.96) total DALYs. Yet, the increase in the age-standardized DALY rates of epilepsy in the 65–69 years group from 147.1 (UI 84.5–231.8) to 208.7 (UI 114.9–333.7) in the 85–89 years age group is noticeable.

In 2017, migraine was the leading cause of NCND in females and males between the ages 35 and 44, contributing to 3149 (UI 2016.3–4546.4), and 1372.6 (UI 846.9–2100.5) DALYs per 100 000, respectively. The sharp increase in the age-standardized DALYs for ADOD was also evident in both sexes after age 65 (Fig. 1).

NCNDs related DALYs by the states

In 2017, across the 50 States, NCNDs related age-standardized DALY rates differences were negligible. Nevertheless, the State with the largest aggregate NCNDs age-standardized DALYs was Montana [1712.7 (UI 1369.2–2137.0)], and the State with lowest DALYs was California [1471.5 (UI 1141.7–1884.9)] (Fig. 2 and Supplementary Table 2). Moreover, the age-standardized DALY rates for migraine, ADOD, epilepsy and tension headache ranked 1st, 2nd, 3rd and 4th, respectively, across the States (Fig. 3). In 2017, the States with the largest age-standardized DALY rates for migraine were District of Columbia [725.5 (UI 461.8–1050.8)], followed by North Carolina and Georgia. South Carolina was the State with the largest age-standardized DALY rates for ADOD [544.9 (UI 496.9–598.1)], followed by Georgia and Alabama. Michigan [151.8 (UI 70.1–287.8)] had the largest age-standardized DALY rates for epilepsy, followed by West Virginia and Louisiana. District of Columbia, Minnesota and Mississippi had the largest rates of tension-type headache (Table 4).

Across all the States, the DALYs (per 100 000) ranking of migraine and ADOD in females were first and second (Supplementary Fig. 3). However, in males, with some exceptions, in the majority of the States, ADOD ranked first, and migraine ranked second in males (Supplementary Fig. 4).

DALYs attributed risks for NCNDs

Of the 84 risks quantified in GBD 2017, high BMI [92.03 (UI 40.4–159.2)], smoking [55.4 (UI 28.4–81.5)], high FPG [47.9 (UI 11.8–101.2)] and alcohol use [31.4 (UI 17.5–51.1)] were the attributable age-standardized DALY risks for aggregate NCNDs (Table 5) and (Supplementary Fig. 5). In 2017, high BMI [556 906.7 (UI 24 579.7–966 510.9)], smoking [313 080.9 (UI 156 446.8–470 030.6)] and high FPG [289 994.5 (UI 67 283.5–613 875.2)] contributed the largest number of DALYs for ADOD, respectively. This followed by alcohol use [113 250.7 (UI 61 973.7–184 139.9)] as the only attributable DALYs risk for epilepsy and smoking [26 766.5 (UI 180 715.7–35 636.0)] for multiple sclerosis (Table 5).

From 1990 to 2017, there was an increase in the proportion of age-standardized DALY rates for ADOD attributable to high BMI (31%) and high FPG (42%), while the proportion of ADOD attributable risk to smoking decreased 58%. DALY rates for epilepsy attributable to smoking increased 6.0%, while this rate for multiple sclerosis attributable to alcohol decreased by 19% (Table 5).

South Carolina had the highest age-standardized DALY rates for ADOD attributable to high BMI [115.4 (UI 201.1–48.9)]. District of Columbia had the highest DALY rates for ADOD attributable to smoking [66.5 (UI 105.7–31.6)]. South Carolina had the highest DALY rates for ADOD attributable to high FPG [65.6 (UI 139.6–15.5)]. Michigan was the State with the highest DALYs for epilepsy attributable to alcohol [41.0 (UI 85.5–15.6)], and the State with the highest DALYs for multiple

Figure 3 Ranking and age-standardized DALY rates for separate NCNDs for both sexes by the States, 2017.
sclerosis attributable to smoking was Montana [11.4 (UI 17.3–6.5)] (Supplementary Table 3).

Discussion

In this article, we aimed to present a comprehensive assessment of the US status and trends in the burden of NCNDs. We found that by contributing to nearly 7 million and nearly 7% of the GBDs, NCNDs were the sixth leading cause of DALY rates in 2017. These estimates have remained nearly stable since 1990 (GBD Neurological Disorders Collaborator Group, 2017; Roth et al., 2018) and confirm that high-income countries are mostly burdened with NCNDs (GBD Neurological Disorders Collaborator Group, 2019). The absolute number of aggregate NCNDs and their age-standardized rates increased by 18.5% and 3.4%, respectively, between 1990 and 2017. The increase in the absolute numbers of DALYs is expected with the population growth and aging. Also, the longer one lives, the longer one is exposed to the behavioural, environmental and metabolic risk factors (GBD 2017 Risk Factor Collaborators, 2018).

Of the individual NCNDs, migraine, followed by ADOD, epilepsy and tension headache, were the top four contributors of DALY rates between 1990 and 2017. Parkinson’s disease DALY rate moved up from the sixth leading NCNDs in 1990 to the fifth in 2017. Of the NCNDs in this study, the largest contributor of all age DALYs were ADOD (2.54%), migraine (2.38%), followed by epilepsy, and Parkinson’s disease, both equally contributing to 0.41% of total DALYs. These findings are consistent with previous findings of GBD, and other national and international studies (Lipton et al., 2001; GBD Neurological Disorders Collaborator Group, 2017; Burch et al., 2018; GBD 2016 Headache Collaborators, 2018) suggesting interventions and quality of medical care aimed at reducing the burden of NCNDs have not been effective enough.


critical points on the page

Table 4 States with the largest age-standardized DALY rates due to migraine, ADOD, epilepsy and tension headache, for both sexes, 2017

| States                      | NCNDs                        | Rates (95% UI) |
|-----------------------------|------------------------------|---------------|
| District of Columbia        | Migraine                     | 725.5 (461.8–1050.8) |
| North Carolina              | Migraine                     | 717.0 (455.1–1039.3) |
| Georgia                     | Migraine                     | 716.7 (455.9–1032.7) |
| South Carolina              | Alzheimer’s disease and other dementias | 544.9 (496.9–598.1) |
| Georgia                     | Alzheimer’s disease and other dementias | 504.9 (460.8–552.5) |
| Alabama                     | Alzheimer’s disease and other dementias | 503.9 (457.3–549.8) |
| Michigan                    | Epilepsy                     | 151.8 (70.1–287.8) |
| West Virginia               | Epilepsy                     | 148.1 (54.8–311.3) |
| Louisiana                   | Epilepsy                     | 145.7 (60.8–278.8) |
| District of Columbia        | Tension-type headache        | 97.4 (54.3–156.6) |
| Minnesota                   | Tension-type headache        | 97.0 (54.7–155.1) |
| Mississippi                 | Tension-type headache        | 97.0 (54.7–154.0) |

Table 5 Attributable all age DALY numbers, age-standardized DALY rates (per 100 000) and age-standardized DALYs percent change risks for ADOD, multiple sclerosis and epilepsy for both sexes in the USA, 1990 and 2017

| NCNDs                      | Aggregate NDs | Alzheimer’s disease and other dementias | Epilepsy | Multiple sclerosis |
|----------------------------|---------------|-----------------------------------------|----------|-------------------|
|                            | High BMI       | Smoking                                 | High FPG  | Smoking           | High BMI       | Smoking          | High FPG  | Smoking           | High BMI       | Smoking           | High FPG  | Smoking           | High FPG  | Smoking           | High FPG  | Smoking           | High FPG  |
|                            | Number/ rate   | Number/ rate                            | Number/ rate | Number/ rate   | Number/ rate   | Number/ rate | Number/ rate | Number/ rate | Number/ rate   | Number/ rate | Number/ rate | Number/ rate | Number/ rate | Number/ rate | Number/ rate | Number/ rate | Number/ rate |
| 1990                       | 240 450.6/69.7 | 439 340.1/124.3                         | 120 738.5/33.6 | 82 189.2/29.6 | 248 450.6/9.7 | 461 764.8/129.4 | 120 738.5/33.6 | 82 189.2/29.6 | 21 664.9/7.6 |
| 2017                       | 556 906.7/92.0 | 313 564.1/55.4                         | 289 945.4/47.9 | 113 250.7/31.4 | 55 690.7/92.1 | 313 080.9/51.1 | 289 945.4/47.9 | 113 250.7/31.4 | 26 766.5/6.1 |
| 1990/2017% change          | 124.1% 31.9%   | –28.6%–55.3%                          | 140.1% 42.6% | 37.7% 6.1%     | 124.1% 31.9%   | –32.2%–58.2% | 140.1% 42.6% | 37.7% 6.1%     | 23.5% 19%   |
other western countries (Stovner et al., 2007; Miller and Cronin-Golomb, 2010; Vukovic et al., 2010; Hirsch et al., 2016; GBD Neurological Disorders Collaborator Group, 2017; Vetvik and MacGregor, 2017). With the exception of other neurological diseases, both females and males experienced an increase in the burden of NCNDs between 1990 and 2017; however, females experienced slightly more increase. The increase with time in the burden of neurological diseases may be explained by the change and improvement of the diagnostic criteria and procedure for suspect cases, and the longer survival of the affected individuals (Dubois et al., 2014; Wijnen et al., 2018; Pinkhardt et al., 2019; Pinto et al., 2019). It is also likely that the decrease in other NDs is the result of the improvement in early detection of the more common neurological cases (Petersen et al., 2001; Iranzo et al., 2006). Among the females, multiple sclerosis, motor neuron diseases and other NDs presented the largest percent increase in DALY rates between 1990 and 2017. In males, Parkinson’s disease, motor neuron diseases and multiple sclerosis were the top three NCNDs with the highest percent of change in DALY rates between 1990 and 2017. These findings suggest the need for further research to understand risk factors related to sex differences in NCNDs. For example, while sex hormones, genetic variations, exposure to and response to stress, and pain have been some of the proposed determining factors for variations in migraine risk in sexes (Peterlin et al., 2011) there is also evidence to support that males are underdiagnosed (Vetvik and MacGregor, 2017).

**NCNDs related DALYs by age**

In 2017, epilepsy was particularly burdensome in children aged 5–9 years. Paediatric epilepsy is a common chronic ND and an important contributor to childhood disability (Aaberg et al., 2017; Lekoubou et al., 2018). Minimizing the burden of childhood epilepsy requires careful implementation and evaluation of home healthcare, outpatient and therapeutic interventions (Kassebaum et al., 2017). The noticeable second peak in the burden of epilepsy in older individual in our findings supports multiple reports that with the increase of aging population it is likely that older people develop new-onset epilepsy (Faught et al., 2012; Choi et al., 2017; Sen et al., 2018; GBD Neurological Disorders Collaborator Group, 2019). In one report, the annual incidence of epilepsy in adults over the age of 65 from 85.9 per 100 000 was reported to be more than 135 per 100 000 in those over the age of 80 (Ziso et al., 2017). With the continuing aging population, the treatment of epilepsy in older individuals amid their comorbid conditions may require the familiarity of the neurologist with the treatment complexity of this disorder to inform their therapeutic decision making better (Sen et al., 2018).

Migraine and tension headaches were highly burdensome for adolescents and young adults, especially the 35- and 44-years old individuals, similar to previous population-based epidemiological studies (Lipton et al., 2001; Burch et al., 2018; Philipp et al., 2019; Hagen et al., 2020). Daily stress due to school work, and lack of adequate sleep, among other factors, precipitate the burdens of these disorders in school-age children and the adult population (Visudtitibhan et al., 2010; Houle et al., 2012; Pellegrino et al., 2018). We found similar results for both females and males with small variations. Females experienced the burden of migraine and tension headaches for a slightly longer period, i.e., until 44 years. For males, the pick age of experiencing these burdens ends at 39 years. Overall, the burden of migraine in the adults, ADOD, and new-onset epilepsy in older adults burden the health of the working population, and with the aging of the population could become among the most costly ailments in the USA.

**NCNDs related DALYs by the States**

In 2017, in all 50 States in the USA, migraine, Alzheimer’s diseases, epilepsy and tension headache held the top four ranks in terms of DALY rates for both sexes. In females, however, in eight States, including Alaska, DC, Hawaii, Iowa, Minnesota, Nebraska, New Hampshire and Vermont tension headache ranked third leading Parkinson’s disease, and in males, in seven States including DC, Maine, Minnesota, Montana, New Hampshire, Texas and Vermont Alzheimer’s disease ranked first leading migraine. In both 1990 and 2017, except for five States, including Alaska, California, DC, Nevada, and New Jersey, the burden of combined NCNDs in terms of DALY rates increased in both sexes. These findings allow benchmarking State-specific NCNDs health loss. The interpretation of differences in the burden of NCNDs by States requires an understanding of the regional risk exposure as well as the role of cultural, social and economic factors influencing NCNDs related availability and accessibility to care.

**DALYs attributed risks for NCNDs**

Our assessment also highlights the crucial part played by the risk factors such as high BMI, smoking, high FPG and alcohol use in contributing to the burden of aggregate and individual NCNDs in both sexes in the USA. In general, these risks have been positively associated with non-communicable diseases and socioeconomic development status of the societies (GBD 2017 Risk Factor Collaborators, 2018). Of the 84 risks, we identified that high BMI, smoking, and high FPG were the contributing risk factors in increasing the burden of Alzheimer’s diseases. While smoking was the contributing risk factor for increasing the burden of multiple sclerosis, and alcohol
use was the contributing risk factor for increasing the burden of epilepsy.

Previous studies have reported the association between high BMI and the risk of dementia. (Arnoldussen et al., 2019; Bianchi et al., 2019; Gregorio et al., 2019; Nam et al., 2019). A new systematic review study indicates the essential role of nutrition in the pathogenesis and evolution of neurodegenerative diseases (Bianchi et al., 2019). According to this review, while high BMI and malnutrition are risk factors for the development of dementia and Parkinson’s disease, Mediterranean diet, a diet rich with nutritional support and calorie-controlled diets are protective against these diseases (Bianchi et al., 2019). It is also suggested that nutritional interventions may provide a better outcome for patients diagnosed with dementia (Chen et al., 2019). Furthermore, the evidence for the direct and possible indirect association between tobacco and Alzheimer’s disease, as well as tobacco and multiple sclerosis, is presented in previous studies (Campdelacreu, 2014; Durazzo et al., 2014; Kvidst et al., 2016; Moss et al., 2017; Mark et al., 2020; Wang et al., 2019).

Also, results from the lab and human research have supported the risk of long-term alcohol use in increasing the risk of epilepsy (Leach et al., 2012; Welch and Derry, 2014; Fu et al., 2016).

It is evident that with population aging, the cost of screening, identification and treatment of NCNDs will increase (Nag and Jelinek, 2019). Researchers have suggested the self-management approach in adopting healthy lifestyle behaviours (Nag and Jelinek, 2019). However, to reduce the health burden of NCNDs requires the willingness and cooperation of the institution of medicine and public health policymakers. Our findings provide theses constituents with information that could have the potential to improve the prevention of NCNDs, as well as the care of those who carry the burden of NCNDs (Orgeta et al., 2019). They also can help those who are accountable for prioritizing investments in research and development for the health and social services that will be required to deal with an aging population (Prince et al., 2016).

Limitations

Our results are limited since GBD estimates are influenced by the quality, time and availability of epidemiological data that supply the GBD study. Besides, the complex grouping of NCNDs sub-causes in GBD is continuously changing due to new additions of diseases. Also, the GBD study does not allow to account for the racial health disparities in the burden of NCNDs.

Also, our findings of the burden of NCNDs in the USA are underestimated since the list of NDs we used is not comprehensive and does not include infectious conditions, stroke, brain and other nervous system cancers, traumatic brain and spinal cord injuries. Indeed, a future iteration of similar study should include stroke, since the contribution of the stroke to the burden of NCNDs is significant (GBD Neurological Disorders Collaborator Group, 2019). Also, GBD uses the global standard population, which is a much younger population compared to the USA, therefore downsizing the burden of NCNDs, which mainly occur in older adults. Additionally, in the list of risk factors in the GBD, we were unable to identify risks attributable to the burden of migraine, tension headache and motor neuron diseases. Since these neurological conditions largely burden the working segment of the population, more research is needed to identify their risk factors, to quantify their level of exposure, and to report trends in exposures and the resulting disease burden. Nevertheless, our findings reveal an increase in the burden of aggregate and separate NCNDs, which can stimulate hypothesis generation on the effects of interventions in the prevention and management of NCNDs.

Conclusions

In summary, between 1990 and 2017, the burden of NCNDs, both in terms of numbers and rates, has increased, suggesting these conditions have exceeded the effect of population growth. Also, the health burden of migraine, ADOD and epilepsy surpassed the burden of the other NCNDs during this time. In 2017, migraines and tension headaches topped the burden of NCNDs for the young adult and adult segments of the USA, while the elderly were the most vulnerable populations to ADOD and epilepsy. Additionally, females were more burdened by migraine, tension headache, ADOD and multiple sclerosis, while the burden of Parkinson’s disease, epilepsy, motor neuron disease and other NDs were more common in males than females. This suggests the need for further research to understand risk factors for sex differences. Moreover, our data show modifying risk factors such as smoking and alcohol use, as well as obesity and high blood sugar, contribute to the burden of ADOD, epilepsy and multiple sclerosis. While risks attributable to smoking decreased for ADOD and multiple sclerosis, the risks attributable to obesity, high blood sugar and alcohol (except for multiple sclerosis) increased between 1990 and 2017. These findings suggest that with the aging of the US population, the burden of NCNDs will continue to impact the health of the individuals and their families, which subsequently will impose a financial burden on society. Moreover, our findings of the burden of NCNDs by sex, age and risk factors in the US inform health policymakers what risk modification strategies in a specific population could have the potential to improve the burden of NCNDs.

Supplementary material

Supplementary material is available at Brain Communications online.
Funding

GBD Study is funded by the Bill and Melinda Gates Foundation and the Institute for Health Metrics and Evaluation at the University of Washington. The funder of the study has no role in study design, data collection, data analysis, data interpretation or writing of this report. All authors had full access to the data in the study and had final responsibility for the decision to submit for publication. This study is funded partly by the National Institutes of Health, National Center for Advancing Translational Science (NCATS), Bethesda, MD; UCLA Clinical and Translational Science Institute (CTSI) (UL1TR001881).

Competing interests

The authors report no competing interests.

References

Aaberg KM, Gunnnes N, Bakken IJ, Lund Soraas C, Berntsen A, Magnus P, et al. Incidence and prevalence of childhood epilepsy: a nationwide cohort study. Pediatrics 2017; 139; e20163908.
Ahmed RM, Devenney EM, Irish M, Ittner A, Naismith S, Ittner LM, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. J Neurol Neurosurg Psychiatry 2016; 87: 1234–41.
Amatniek J, Sorra K, Lauren F, Hauser W. Age and gender specific patterns of neurologic illness. In: M Leagro, editor. Principles of gender-specific medicine, Vol. 2. Amsterdam: Elsevier; 2010. p. 113–28.
Arnoldussen IAC, Gustafson DR, Leijser EM, de Leeuw FE, Kiliaan AJ. Adiposity is related to cerebrovascular and brain volumetry outcomes in the RUN DMC study. Neurology 2019, 93: e864–878.
Barron M, Rosario R, Elteriefi R, Pike C. Sex-specific effects of high fat diet on indices of metabolic syndrome in 3XG-AD mice: implications for Alzheimer’s disease. PLoS One 2013; 8: e78554.
Belbasis L, Bellou V, Evangelou E, Ioannidis JP, Tzoulaki I. Environmental risk factors and multiple sclerosis: an umbrella review of systematic reviews and meta-analyses. Lancet Neurol 2015; 14: 263–73.
Bianchi VE, Herrera PF, Laura R. Effect of nutrition on neurodegenerative diseases. A systematic review. Nutr Neurosci 2019; 1–25.
Bruzzone R, Dubois-Dalcq M, Grau GE, Griffin DE, Kristensson K. Infectious diseases of the nervous system and their impact in developing countries. PLoS Pathog 2009; 5: e1000199.
Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from 1999 to 2012. Neurology 2015; 84: 459–66.
Campdelacreu J. Parkinson disease and Alzheimer disease: environmental risk factors. Neurologia 2014; 29: 121–30.
Chen TB, Weng SC, Chou YY, Lee YS, Liang CK, Lin CS, et al. Predictors of mortality in the oldest old patients with newly diagnosed Alzheimer disease in a residential aged care facility. Dement Geriatr Cogn Disord 2019; 48: 93–104.
Choi H, Park A, Elkind MS, Longstreth WT, Ton TG, Onchiri F. Predictors of incident epilepsy in older adults: the Cardiovascular Health Study. Neurology 2017; 88: 870–7.
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614–29.
Durazzo TC, Mattsson N, Weiner MW; Alzheimer’s Disease Neuroimaging Initiative. Smoking and increased Alzheimer’s disease risk: a review of potential mechanisms. Alzheimers Dement 2014; 10: S122–145.
Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 459–80.
Fu X, Guo Z, Gao C, Chu Q, Li J, Ma H, et al. Long-term alcohol-induced activation of mammalian target of rapamycin is a key risk factor of epilepsy. Med Sci Monit 2016; 22: 3975–80.
GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet Neurol 2017; 16: 877–97.
GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954–76.
GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1923–94.
GBD Collaborator, Kassebaum NJ, Arora M, Barber RM, Bhatta ZA, Brown J, Carter A, et al. Global regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1603–58.
GBD Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019; 18: 459–80.
Gooch CL, Pracht E, Borenstein AR. The burden of neurological disease in the United States: A summary report and call to action. Ann Neurol 2017; 81: 479–84.
Gordon E, Devinsky O. Alcohol and marijuana: effects on epilepsy and use by patients with epilepsy. Epilepsia 2001; 42: 1266–72.
Gregorio E, Patrzyk LH, Fribrantz AKB, Bonini JS; Cambruzzi DH, Diedrich C, et al. Nutritional and hematological factors associated with the progression of Alzheimer’s disease: a cohort study. Rev Assoc Med Bras (1992), 2019; 65: 222–31.
HaaXma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 819–24.
Hagen K, Stovner LJ, Zwart JA. Time trends of major headache diagnoses and predictive factors. Data from three Nord-Trondelag health surveys. J Headache Pain 2020; 21: 24.
Harbo HF, Isobe N, Berg-Hansen P, Bos PSB, Caillier SJ, Gustavsen MW, et al. Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis. Mult Scler 2014; 20: 660–8.
Hirsch L, Jette N, Frolkis A, Steeves AT, Pringsheim T. The incidence of migraine and tension-type headache. A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954–76.
Houle TT, Butscher AE, Turner DP, Smitherman TA, Rains JC, Penzien DB. Stress and sleep duration predict headache severity in chronic headache sufferers. Pain 2012; 153: 2432–40.
Institute for Health Metrics and Evaluation (IHME). Available from: https://vizhub.healthdata.org/gbd-compare/ (November 2019, date last accessed).
Institute for Health Metrics and Evaluation (IHME). About GBD. The global burden of disease: a critical resource for informed policy making. Available from: http://www.healthdata.org/gbd/about (November 2019, date last accessed).
Iranzo A, Molinuevo JL, Santamaría J, Serradell M, Martí MJ, Valldècoriola FY, et al. Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006; 5: 572–7.

Jancia A, Aarli JA, Prilipko L, Dua T, Saxena S, Saraceno B. WHO/ WFN Survey of neurological services: a worldwide perspective. J Neurol Sci 2005; 236: 255–61.

Kassebaum N, Kyu HH, Zoëckler L, Olsen HE, Thomas K, Pinho C, Janca A, Aarli JA, Prilipko L, Dua T, Saxena S, Saraceno B. WHO/Philipp J, Zeiler M, Woerber C, Wagner G, Karwautz AFK, Steiner TJ, et al. No association of tobacco use and disease activity in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 2016; 3: e260.

Leach JP, Mohanraj R, Borland W. Alcohol and drugs in epilepsy: pathophysiology, presentation, possibilities, and prevention. Epilepsia 2012; 53: 48–57.

Lekoubou A, Bishu KG, Ovbiagele B. The direct cost of epilepsy in children: evidence from the Medical Expenditure Panel Survey, 2003-2014. Epilepsy Behav 2018; 83: 103–7.

Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Measuring the global burden of disease and risk factors, 1990-2001. Global burden of disease and risk factors. Washington (DC): World Bank, The International Bank for Reconstruction and Development/ The World Bank Group; 2006.

Marck CH, das Nair R, Grech LB, Borland R, Constantinescu CS. Modifiable risk factors for poor health outcomes in multiple sclerosis: the urgent need for research to maximise smoking cessation success. Mult Scler 2020; 26: 266–71.

Miller IN, Cronin-Golomb A. Gender differences in Parkinson’s disease: clinical characteristics and cognition. Mov Disord 2010; 25: 2695–703.

Moss BP, Rensel MR, Hersh CM. Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics 2017; 14: 999–1017.

Nag N, Jelinek GA. A narrative review of lifestyle factors associated with Parkinson’s disease risk and progression. Neurodegener Dis 2019; 19: 51–9.

Nam GE, Park YG, Han K, Kim MK, Koh ES, Kim ES, et al. BMI, weight change, and dementia risk in patients with new-onset type 2 diabetes: a nationwide cohort study. Diabetes Care 2019; 42: 1217–24.

Neiman J, Haapaniemi HM, Hillbom M. Neurological complications of drug abuse: pathophysiological mechanisms. Eur J Neurol 2000; 7: 595–606.

Orgeta V, Mukadam N, Sommerlad A, Livingston G. The Lancet Commission on Dementia Prevention, Intervention, and Care: a call for action. Ir J Psychol Med 2019; 36: 85–8.

Pellegrino ABW, Davis-Martin RR, Houle TT, Turner DP, Smitherman TA. Perceived triggers of primary headache disorders: a meta-analysis. Cephalalgia 2018; 38: 1188–98.

Peterlin B, Saurabh G, Ward T, MacGregor A. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol 2017; 16: 76–87.

Vina J, Ana L. Why women have more Alzheimer’s disease than men: gender and mitochondrial toxicity of amyloid-beta peptide. J Alzheimer’s Dis 2010; 20: 527–33.

Visudthibhan A, Thampratankul L, Khongkhathithum C, Okascharoen C, Siripornapanich VS, Chiemchanya, S, et al. Migraine in junior high-school students: a prospective 3-academic-year cohort study. Brain Dev 2010; 32: 855–62.

Vukovic V, Plavec D, Pavelin S, Janculjak D, Ivanovic M, Demarin V. Prevalence of migraine, probable migraine and tension-type headache in the Croatian population. Neuroepidemiology 2010; 35: 59–65.

Wang Z, Xie J, Wu C, Xiao G. Correlation between smoking and passive smoking with multiple sclerosis and the underlying molecular mechanisms. Med Sci Monit 2019; 25: 893–902.

Welch KA, Derry C. Mild traumatic brain injury and epilepsy: alcohol misuse may underpin the association. J Neurol Neurosurg Psychiatry 2014; 85: 593.

Whitmer R, Gunderson E, Quesenberry C, Zhou J, Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Car 2007; 4: 103–109.

Wijnen BFM, Schar SL, De Kinderen RJA, Colon AJ, Ossenblok PPW, Evers SMMA. Burden of disease of people with epilepsy during an optimized diagnostic trajectory: costs and quality of life. Epilepsy Res 2018; 146: 87–93.

Yegambara M, Manivannan B, Halden R. Role of environmental contaminants in the etiology of Alzheimer’s disease: a review. Bentham Sci 2015; 12: 116–146.

Ziso B, Dixon PA, Marson AG. Epilepsy management in older people: lessons from National Audit of Seizure management in Hospitals (NASH). Seizure 2017; 50: 33–37.